Drug Trial Radar · NCT06660654
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
335
Planned (sponsor's estimate)
Start
Jan 6, 2025
Primary completion
Dec 30, 2029
Study completion Dec 30, 2029
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Oct 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pan-tumor trial is designed as a signal-seeking trial to assess efficacy and safety of raludotatug deruxtecan (R-DXd) monotherapy in locally advanced or metastatic solid tumors with various cadherin-6 (CDH6) expression levels, including gynecological cancers (endometrial cancer, cervical cancer, and non-high-grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and clear cell renal cell carcinoma \[ccRCC\]).
Conditions
- Advanced Solid Tumor
- Metastatic Solid Tumors
Interventions
Raludotatug deruxtecanDrug
IV administration Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate as Assessed by the Investigator (All Cohorts Except ccRCC)Time frame: Baseline up to 48 months
- Disease Control Rate (DCR) as Assessed by the Investigator (ccRCC Cohort Only)Time frame: Baseline up to 48 months
- Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs) (All Cohorts)Time frame: Baseline up to 48 months
Locations
48 sites in 9 countries. Site status is shown where the registry gives one.
Northside Hospital
Marietta, Georgia
University of Michigan Comprehensive Cancer Center Michigan Medicine
Ann Arbor, Michigan
Astera Cancer Care
East Brunswick, New Jersey
Women's Cancer Care Associates
Albany, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Clinical Research Alliance
Westbury, New York
West Cancer Center and Research Institute
Germantown, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
UZ Leuven Gynaec onco
Leuven, Belgium
ZAS Sint-Augustinus
Wilrijk, Belgium
Hunan Cancer Hospital
Changsha, China
Shanghai Cancer center
Shanghai, China
Herlev og Gentofte Hosp
Copenhagen, Denmark
François Baclesse Center
Caen, France
Centre Georges-François Leclerc
Dijon, France
Centre Oscar Lambret
Lille, France
Centre Leon Berard
Lyon, France
Grp Hsp Diac Croix Saint Simon
Paris, France
Cario - Centre Armoricain de Radiothérapie, Imagerie Médicale Et Oncologie
Plérin, France
Ico - Site René Gauducheau
Saint-Herblain, France
Institut Claudius Regaud
Toulouse, France
Gustave Roussy
Villejuif, France
AO per lEmergenza Cannizzaro
Catania, Italy
Irccs Ospedale San Martino
Genova, Italy
IRCCS Dino Amadori - IRST
Meldola, Italy
IRCCS San Raffaele
Milan, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Federico II Hospital
Naples, Italy
Azienda Ospedaliera S Maria
Terni, Italy
Hyogo Cancer Center
Akashi, Japan
National Cancer Center Hospital
Chūōku, Japan
National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan
Saitama Medical University International Medical Center
Hidaka, Japan
National Cancer Center Hospital East
Kashiwa, Japan
The Cancer Institute Hospital of Jfcr
Kōtoku, Japan
Aichi Cancer Centre
Nagoya, Japan
Osaka International Cancer Institute
Osaka, Japan
National Cancer Center
Goyang-si, South Korea
Severance Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.